For its second fiscal quarter (ending June 30), EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) has reported E.P.S. of $-0.58 compared to $-0.61 a year ago. This result fell short of the consensus estimate of $-0.53 by $-0.05. For the latest four quarters through June 30, E.P.S. were $-1.79 versus $-2.82 for the same period a year ago.
Recent Price Action
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) stock declined by -4.1% on 8/7/24. The shares closed at $8.65. However, trading volume in this decline was below average at 80% of normal. The stock has been extremely weak relative to the market over the last nine months and has declined -9.1% during the last week.
Current PriceTarget Research Rating
EYPT is expected to continue to be a modest Value Eraser reflecting capital returns that are forecasted to fall short of the cost of capital.
EyePoint Pharmaceuticals has a current Value Trend Rating of F (Lowest Rating). This rating combines inconsistent signals from two proprietary PTR measures of a stock’s attractiveness. EyePoint Pharmaceuticals has a neutral Appreciation Score of 46 but a very low Power Rating of 3, with the Lowest Value Trend Rating the result.
Rating Review
In light of this new information and negative market action we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment